ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Ligand Licenses Drugs To Start-Up Viking

by Rick Mullin
June 2, 2014 | APPEARED IN VOLUME 92, ISSUE 22

Ligand Pharmaceuticals has licensed the rights to five drug research programs to Viking Therapeutics, a biotech start-up specializing in metabolic and endocrine disorders. The deal includes Ligand’s FBPase inhibitor program for type 2 diabetes and its selective androgen receptor modulator (SARM) program for muscle wasting. Each program includes a payment to Ligand in Viking equity at the time of any outside financing, milestone payments, and royalties on future sales. Ligand will extend a $25 million loan to Viking to cover expenses.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment